Last reviewed · How we verify
Zipsor®
Zipsor is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain.
Zipsor is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain. Used for Mild to moderate acute pain in adults.
At a glance
| Generic name | Zipsor® |
|---|---|
| Also known as | Diclofenac |
| Sponsor | Depomed |
| Drug class | NSAID (nonsteroidal anti-inflammatory drug) |
| Target | COX-1 and COX-2 (cyclooxygenase enzymes) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Zipsor contains diclofenac potassium, which blocks COX-1 and COX-2 enzymes responsible for prostaglandin production. By reducing prostaglandins, the drug decreases inflammatory mediators and provides analgesic and anti-inflammatory effects. Zipsor is formulated as an immediate-release oral capsule for rapid onset of action.
Approved indications
- Mild to moderate acute pain in adults
Common side effects
- Dyspepsia
- Abdominal pain
- Nausea
- Diarrhea
- Headache
- Dizziness
- Gastrointestinal bleeding (rare but serious)
Key clinical trials
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery (NA)
- Continue ESPB & Continue ESPB Combined With SAPB for Thoracotomy (NA)
- Assessment of Different Medications in Modifying the Efficacy of Anesthesia in Mandibular Molars With Acute Irreversible Pulpitis (PHASE4)
- Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis (EARLY_PHASE1)
- Quantification of Diclofenac 2.32% (Voltaren) in Rinse Water After Different Application Methods (NA)
- Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp (PHASE4)
- A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zipsor® CI brief — competitive landscape report
- Zipsor® updates RSS · CI watch RSS
- Depomed portfolio CI